English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 8 November 2024, 20:23 HKT/SGT
Share:
ITC's Final Decision Confirms Innoscience's Customers Remain Unaffected by the Innoscience-EPC Patent Row
- Finds No Infringement of the '508 Patent
- and Paves the Way for Designing Around the Remaining '294 Patent Currently Stands Challenged as Invalid at USPTO

HONG KONG, Nov 8, 2024 - (ACN Newswire) - Innoscience Technology, a company founded to create a global energy ecosystem based on high-performance, low-cost, gallium-nitride-on-silicon (GaN-on-Si) power solutions, announced today that the U.S. International Trade Commission’s (“ITC”) November 7, 2024 final determination has confirmed the ability of Innoscience’s customers to import their products into U.S. remain unaffected by the ongoing patent dispute between Innoscience and Efficient Power Conversion Corporation (“EPC”).

In May last year, EPC launched a lawsuit against Innoscience at the ITC, falsely alleging infringement of EPC’s ’508 and ’294 patents. Following an administrative law judge’s initial determination in the past July finding no infringement of claim 1 (the only asserted claim) of the ’508 patent, the latest ITC final determination once again affirmed no violation as to this patent—a huge success for Innoscience.

The final determination, however, affirmed the part of the judge’s initial determination that found violation as to claims 2 and 3 the ’294 patent. The ITC hence has determined to issue a limited exclusion order prohibiting importation of certain accused Innoscience chips. Innoscience disagrees with and will appeal this ruling. This is at least because the ‘294 patent is invalid. Indeed, the U.S Patent and Trademark Office (“USPTO”) instituted an inter partes review (“IPR”) challenging all claims of the ’294 patent under four different grounds and has agreed with Innoscience’s invalidity arguments. The ’294 IPR decision will issue in March 2025.

Innoscience also notes it is established U.S. law that the limited exclusion order does not prohibit Innoscience’s customers from importing end products that use the accused chips. Moreover, since the final decision clarified the meaning of the claim term “compensated GaN layer,” which is at the center of the dispute surrounding the ’294 patent, it has provided clear guidance for Innoscience to design around the ’294 patent by avoiding use of the “compensated GaN layer.” Innoscience already has the design around in place and will release the new products soon.  

Accordingly, the EPC litigation shall have no impact on Innoscience’s customers. Moreover, Innoscience will continue to solve the dispute with EPC through appeals in court and invalidity challenges at the USPTO, and is confident that it will achieve a final complete victory. 



Topic: Press release summary Sectors: Electronics
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence  
Feb 9, 2026 13:28 HKT/SGT
JCB Announces Collaboration with Resorts World Sentosa in Singapore  
Monday, February 9, 2026 1:00:00 PM
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026  
Monday, February 9, 2026 10:00:00 AM
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group  
Feb 8, 2026 23:30 HKT/SGT
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.  
Feb 7, 2026 05:45 HKT/SGT
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets  
Feb 6, 2026 17:45 HKT/SGT
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share  
Feb 6, 2026 17:01 HKT/SGT
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization  
Feb 6, 2026 16:34 HKT/SGT
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis  
Feb 6, 2026 14:17 HKT/SGT
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025  
Feb 6, 2026 13:13 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575